Header Logo

Connection

YUKA MORIKAWA to Drug Evaluation, Preclinical

Back to Details
This is a "connection" page, showing publications YUKA MORIKAWA has written about Drug Evaluation, Preclinical.
YUKA MORIKAWA
Connection Strength
0.040
Drug Evaluation, Preclinical
  1. Synergistic reduction in albuminuria in type 2 diabetic mice by esaxerenone (CS-3150), a novel nonsteroidal selective mineralocorticoid receptor blocker, combined with an angiotensin II receptor blocker. Hypertens Res. 2020 11; 43(11):1204-1213.
    View in: PubMed
    Score: 0.040
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.